Fugacar inhibits the formation of the worm microtubules and causes the worms' glucose depletion.
Pharmacology: Pharmacokinetics: Following administration of 100 mg twice daily for 3 consecutive days, plasma levels of Fugacar and its primary metabolite, the 2-amine, do not exceed 0.03 mcg/mL, respectively. All metabolites are devoid of anthelmintic activity. In man, approximately 2% of administered Fugacar is excreted in urine and remainder in the faeces as unchanged drug or a primary metabolite.
Microbiology: With a potent anthelmintic activity against nematodes. Fugacar is effective against Enterobius vermicularis (pinworm), threadworm, Ascaris lumbricoides (large roundworm), Ancylostoma duodenale (hookworm) and Trichuris trichiura (whipworm).